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Abstract
Purpose: To investigate the relationship between age and axillary lymph node (LN) involvement in Chinese breast cancer
patients, and to replicate a recently identified piecewise relationship between age and LN involvement.
Methods: A dataset, consisting of 3,715 patients (with complete information on study variables) with operable breast cancer
consecutively surgically treated between 1996 and 2006, was derived from the database of Shanghai Cancer Hospital.
Univariate and multivariate logistic regression were employed to analyze the relationship between age and LN. We
subsequently performed a similar analysis on another dataset including 1,832 consecutive patients treated between 2007
and 2008 to replicate our findings in the first dataset.
Results: A U-shaped relationship (previously observed in two European populations) between age and LN status failed to be
replicated in our dataset of Chinese patients. Instead, we observed a linear rather than piecewise relationship. After
multivariate adjustment, the linear relationship was still present. Moreover, the interaction between age and LN
involvement was not modified by tumor size. The odds of LN involvement decreased by 1.5% for each year increase in age
(OR 0.985, 95% CI 0.979–0.991, P,0.001). Breast cancer subtypes were also associated with LN status. Proportions of basal-
like and ERBB2+ subtypes decreased with increasing age. The observations in the first dataset were successfully replicated in
a second independent dataset.
Conclusion: We confirmed a straightforward but not piecewise relationship between age and LN status in Chinese patients.
The different pattern between Chinese and European elderly patients should be considered when making clinical
decisions.
Citation: Yu K-D, Li J-J, Di G-H, Wu J, Shen Z-Z, et al. (2010) A Straightforward but Not Piecewise Relationship between Age and Lymph Node Status in Chinese
Breast Cancer Patients. PLoS ONE 5(6): e11035. doi:10.1371/journal.pone.0011035
Editor: Joseph Najbauer, City of Hope National Medical Center, United States of America
Received January 6, 2010; Accepted May 17, 2010; Published June 9, 2010
Copyright:  2010 Yu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research is supported by grants from the National Basic Research Program of China (2006CB910501), 2009 Youth Foundation of Shanghai Public
Health Bureau, 2009 Youth Foundation of Shanghai Medical College, and the National Natural Science Foundation of China (30971143, 30972936). The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: zhimingshao@yahoo.com
. These authors contributed equally to this work.
Introduction
Despite relatively lower incidence of breast cancer in Asian
countries than in the west [1], China has documented a 20–30%
increase in urban areas over the past decade [2,3]. The disease
status of axillary lymph nodes (LNs) is the most significant
prognostic factor for patients with breast cancer [4] [5]. At
present, although the use of sentinel LNs identification and
sampling procedure could be reliably performed in selected early
stage patients by a trained multidisciplinary team [6], axillary LN
dissection (ALND) is still the mainstay of the surgical management
of breast cancer in China [3].
The determination of factors associated with axillary LN
involvement may help us predict or identify a subgroup of patients
with a low rate of node involvement. Regarding the relationship
between age and LN status, some investigator suggested the older
patients were associated with an increased probability of nodes
involvement [7], while others proposed that tumors of elderly
patients were biologically more favorable [8] and had a decrease
in LN involvement [9]. In addition, Wildiers et al. recently
reported a large sample size study (referred to as the Leuven study)
examining the relationship between patient age and risk of axillary
LN involvement [10]. Interestingly, they identified a piecewise
effect of age on LN positivity. Because of these discordant results,
we here decided to perform a large scale retrospective analysis for
two aims. One aim was to validate the piecewise U-shaped
relationship between age and LN status, which had been
replicated in two European patient populations; the other was to
explore the relationship between age and LN status in Chinese
breast cancer patients, which has been seldom studied.
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Study subjects and variables
The study subjects were from the Breast Malignancy Database
established by the Department of Surgery, Shanghai Cancer
Hospital of Fudan University in Shanghai, China. The database
has more than 10,000 case records including detailed clinicopath-
ologic data and follow-up results. The information of this database
has been reported elsewhere [3]. All patients gave written
informed consent for their information to be stored in the hospital
database and used for research, and this study was approved by
the Ethical Committee of Shanghai Cancer Hospital of Fudan
University. The first dataset we used was derived from the entire
database of the period between 1996 and 2006, in which period
there were total 6,030 consecutive patients with breast malignan-
cies. Patients selected for the present retrospective study fulfilled
the following inclusion criteria: (1) female patients diagnosed with
ipsilateral invasive breast cancer. Patients with breast carcinoma
in situ (with or without microinvasion) and breast sarcoma were
excluded; (2) all these patients received primary surgery in our
hospital; (3) the pathological examination of patients’ tumor
specimens was performed in the Department of Pathology in our
hospital; (4) patients were operable without any evidence of
metastases at diagnosis. Preoperative evaluation and examination
had been described previously [11]; (5) patients receiving
neoadjuvant systemic therapy (chemotherapy and/or hormone
therapy) and preoperative irradiation were excluded. A preoper-
ative diagnostic biopsy was allowed. As a result, 4,263 patients met
all these criteria (see Figure 1 for patient selection).
In order to validate the results of the Leuven study, we chose
the following variables for analysis: age at diagnosis (year),
pathological tumor size (the largest diameter), tumor grade,
pathology (invasive ductal cancer vs. invasive lobular cancer vs.
other invasive cancers), involvement of axillary LN (number of
positive nodes), estrogen receptor (ER) and progesterone receptor
(PR) status, and HER2/neu status. Age at diagnosis and tumor
sizes were recorded as continuous variables, the other variables
treated as categorical data. Axillary LN status was analyzed either
as a binary variable (positive or negative) or as a ternary variable
according to the number of involved LNs (0, 1–3, or $4).
Determination of tumor grading, ER, PR and HER2 status was
performed by pathologists in the Department of Pathology in our
hospital. The work was done according to established procedures
which had been described elsewhere [11].
According to molecular profile of breast cancer subtypes
[12,13], the immunohistochemical (IHC) surrogates for four
major subtypes had been developed: luminal A (ER+ and/or
PR+, HER22), luminal B (ER+ and/or PR+, HER2+), ERBB2+
(ER2,P R 2, HER2+), and basal-like (ER2,P R 2, HER2-, also
known as triple-negative) [14]. In the present study, we analyzed
the status of ER, PR and HER2 receptors in a combined manner.
The luminal A and luminal B breast cancer were combined as the
‘luminal-like subtype’ (ER+ and/or PR+, any HER2 status).
Of the 4,263 eligible breast cancer patients, some of them had
missing values of the studied variables, 4.3% of tumor size
(n=182), 12.5% of combined receptors status (n=532), and
1.4% of axillary LN status (n=58). Of note, 35.7% cases
(n=1,523) were not evaluated for tumor histological grade (most
breast carcinomas of special histologic types such as mucinous,
tubular, medullary, and papillary carcinoma were not evaluated).
Because of such a high proportion, we did not exclude those cases
with missing values of tumor grade. Finally, 3,715 patients
(87.1%) with complete information of age, tumor size, pathology,
LN status, and ER, PR and HER2 status were selected for
analysis.
Replication of the observed relationship in Chinese
patients
The second dataset for validation was also derived from the
entire database, and the patients corresponded to the breast cancer
cases of the period between 2007 and 2008 (Figure 1). During
that period, more than 3,000 consecutive breast malignancy
patients received primary surgical treatment in our department. A
total 3,112 cases were entered into our database. Among these,
2,172 patients fulfilled the inclusion criteria applied for patient
selection in the first dataset.
The IHC data (ER/PR/HER2) in the second dataset is
currently being checked and replenished, and only half of patients
(n=997, 45.9%) in the second dataset are available for ER, PR
and HER2. Therefore, we excluded the independent variable
‘‘breast cancer subtype’’ from further analysis. Percentages of
other missing data on tumor size, tumor grade and LN
involvement were 15.0%, 20.4% and 3.0%, respectively. Finally,
we selected 1,832 (84.3%) patients with complete information
(except tumor grade and subtype) for analysis. Similar to the
situation in the first dataset, we performed multivariate logistic
regression to predict LN involvement using three independent
variables (age, tumor size and pathology).
Statistical analysis
We regressed on age using nonparametric logistic regression
based on smoothing (LOWESS) method [10] to explore the
relationship pattern in our study subjects. In descriptive statistics,
associations between categorical variables were tested using
Pearson’s x
2 test. The odds ratios (OR) with 95% confidence
Figure 1. Patient selection and patient subsets analyzed. # 5
variables denote lymph node, age, pathology, tumor size, and subtype
* 4 variables denote lymph node, age, pathology, and tumor size.
doi:10.1371/journal.pone.0011035.g001
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involvement (yes or no) were calculated using logistic regression.
We employed multivariate logistic regression to predict LN
involvement (method: backward stepwise, likelihood ratio). For
the first dataset, the regression model was established based on
four basic independent variables (age, tumor size, pathology and
subtype). Similarly, for the second dataset, the model was
established based on three basic independent variables (age,
tumor size and pathology). Breast cancer subtype was chosen for
modeling in the first dataset, but not in the second dataset.
Hosmer-Lemeshow test was performed to assess goodness-of-fit of
model. A P-value less than or equal to 0.05 was considered
statistically significant. Statistical analysis was performed using
Stata/SE version 10.0 (Stata, College Station, TX) and SPSS
Software version 12.0 (SPSS, Chicago, IL, USA).
Results
The basic characteristics of the patients from the first dataset
(1996–2006, n=3,715) are shown in Table 1. Since more than
half of breast cancer patients in China are premenopausal and the
patients older than 80 years are relatively few [2], we arbitrarily
divided the study subjects into five groups according to age:
younger than 40 years, 40–49 years, 50–59 years, 60–69 years,
and 70 years and older.
A linear relationship between age and LN involvement in
univariate analysis
As the Leuven study previously demonstrated a U-shaped
relationship between age and LN involvement [10], we first tried
to replicate that result in our population. However, in our study,
Table 1. Tumor characteristics and lymph node involvement according to age in the two datasets.
Parameter Age category (years)
,40 40–49 50–59 60–69 $70 Total
The first dataset, n 329 1250 1133 593 347 3,715
Median tumor size, cm 2.3 2.5 2.5 2.7 3.0 2.5
Histology, % Ductal 89.3 90.0 89.8 85.5 81.3 88.3
Lobular 3.1 3.7 3.1 4.6 3.2 3.5
Other 7.7 6.3 7.1 9.9 15.6 8.1
Tumor grade*, % I 1.0 1.6 1.5 1.7 1.7 1.5
II 38.8 44.0 51.4 48.4 47.8 46.8
III 23.2 19.3 17.9 17.0 12.7 18.3
Missing 37.0 35.1 29.2 32.9 37.8 33.4
Involved lymph nodes, % Negative 46.2 53.4 52.4 60.5 62.5 54.3
Positive 53.8 46.6 47.6 39.5 37.5 45.7
1–3 28.3 29.6 28.9 23.4 23.6 27.7
$4 25.5 17.0 18.7 16.0 13.8 18.0
ER, % + 42.6 47.4 56.8 66.3 66.9 54.6
PR, % + 43.6 54.6 48.1 52.3 52.7 50.9
HER2, % + 21.9 23.0 25.5 21.2 16.0 22.7
Subtypes, % Luminal-like 57.7 65.8 67.3 74.2 77.2 67.8
ERBB2+ 13.0 10.8 10.3 7.4 6.1 9.9
Basal-like 29.3 23.4 22.3 18.4 16.7 22.3
The second dataset
&, n 242 534 637 295 124 1,832
Median tumor size, cm 2.0 2.0 2.1 2.2 2.0 2.0
Histology, % Ductal 96.7 94.2 94.0 90.2 83.1 93.1
Lobular 0.4 2.1 0.8 0.7 2.4 1.2
Other 2.9 3.7 5.2 9.2 14.5 5.7
Tumor grade*, % I 2.5 3.7 2.2 2.7 3.2 2.8
II 54.5 56.9 60.6 61.4 60.5 58.8
III 37.2 31.5 30.3 27.5 25.8 30.8
Missing 5.8 7.9 6.9 8.5 10.5 7.5
Involved lymph nodes, % Negative 49.2 52.8 55.7 58.6 62.9 55.0
Positive 50.8 47.2 44.3 41.4 37.1 45.0
1–3 28.5 29.2 26.7 25.1 23.4 27.2
$4 22.3 18.0 17.6 16.3 13.7 17.8
*Data of tumor grade are available in 66.6% subjects in the first dataset and 92.5% in the second dataset.
&Immunohistochemical data on ER/PR/HER2 status in the dataset of 2008 is currently being checked and replenished. Only half of values (n=997, 45.9%) are available.
Therefore, the analysis of variable ‘‘breast cancer subtype’’ is not performed in the second dataset.
doi:10.1371/journal.pone.0011035.t001
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piecewise effect of age on LN status (Figure 2A). Age was
negatively related to LN involvement in the whole group (OR per
year 0.985, 95% CI 0.979–0.990 Table 2). Other independent
variables including tumor size (OR per centimeter 1.244, 95% CI
1.182–1.310), pathology (OR 0.625, 95% CI 0.551–0.709), ER
(OR of positive 0.645, 95% CI 0.566–0.735) and PR status (OR of
positive 0.820, 95% CI 0.720–0.933), and HER2 status (OR of
positive 1.363, 95% CI 1.167–1.591) had significant relationships
with LN involvement. When combining ER, PR and HER2 as
variables of breast cancer subtype, ERBB2+ and basal-like
subtypes, both contributed to the risk of LN involvement (OR
1.773, 95% CI 1.543–2.037).
The repeatable linear relationship between age and LN
status
In the second dataset, the univariate effect of age on LN
involvement using LOWESS smoothing method also displayed a
similar linear relationship that was observed in the first study
(Figure 2B). Age was negatively related to LN involvement
(OR per year 0.986, 95% CI 0.978–0.994 Table 2). Other
independent variables associated with LN involvement included
tumor size (OR per centimeter 1.244, 95% CI 1.182–1.310) and
pathology (OR 0.565, 95% CI 0.449–0.711). When we combined
the first dataset and the second dataset together, the LOWESS
smoothing plot showed the same trend, i.e., that older women had
a lower probability of LN involvement (Figure 2C).
Multivariate logistic regression confirmed the linear
relationship
After adjustment of other predictors, the linear relationship
between age and LN involvement was still present. As the results
from the first dataset showed, the odds of LN involvement
decreased by 1.5% for each year increase in age (OR 0.985, 95%
CI 0.979–0.991), increased by 25–30% for each centimeter
increase in tumor size (OR 1.262, 95% CI 1.197–1.331), and
increased in ERBB2+ and basal-like subtypes (OR 1.303, 95% CI
1.203–1.411). Special histologic type (such as mucinous, tubular,
medullary, and papillary carcinoma) also displayed a decreased
risk of LN involvement compared with invasive ductal cancer.
Similarly, the reverse relationship between age and LN involve-
ment was successfully replicated.
Since the increase in age had a negative effect on LN
involvement, and no piecewise effect was observed, we therefore
did not develop piecewise models for prediction of node
involvement. One logistic regression model worked well for
patients of any age. We regressed a model using four independent
variables (age, size, pathology and subtype) from the first dataset
and three independent variables (age, size, and pathology) from
the second dataset, respectively. The goodness-of-fit tests suggested
that both models were good fits. Hazard ratios of each
independent variable are presented in Table 2. The probability
of lymph node involvement was estimated as e
L/(1+e
L), where the
value of L was derived by multivariate logistic regression analysis.
The dependent variable was ‘‘lymph node involvement’’, and the
independent variables for the first dataset model were age,
pathology, size, and subtype; the independent variables for the
second dataset model were age, pathology, and size. The values of
age and size were continuous. For pathology, invasive ductal=1,
invasive lobular=2, and other invasive carcinomas=3; for
subtype, luminal-like=1, ERBB+=2, and basal-like=3.
Formula for the first model:
L1~0:125z({0:015)|Agez({0:478)|Pathology
z0:233|Sizez0:265|Subtype:
Formula for the second model:
L2~0:219z({0:011)|Age
z({0:582)|Pathologyz0:348|Size:
No modifying effect of tumor size on the relationship
between age and LN involvement
The Leuven study revealed an interaction between age and
tumor size on the frequency of LN involvement. It was
demonstrated that the piecewise effect for age on the LN
involvement was clearer in small tumors but not in tumors larger
than3.5 cm[10].However,inourstudy,weobserved thatthe effect
Figure 2. Relation between age and lymph node involvement
based on univariate nonparametric smoothing method. (A) The
first dataset using univariate nonparametric smoothing method
(n=3,715) (B) The second dataset using univariate nonparametric
smoothing method (n=1,832) (C) The combined two datasets using
univariate nonparametric smoothing method (n=5,547).
doi:10.1371/journal.pone.0011035.g002
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subgroup analysis (Table 3). Despite subdivision of the study
subjects according to tumor size (#2.0 cm, 2.1–3.5 cm, $3.6 cm),
the reverse relationship between age and LN status did change
either in the first dataset or in the combined dataset. Furthermore,
the predicted probability of LN involvement was negatively
associated with age in each subgroup (Figure 3A) in the first
dataset, which was replicated in the second dataset (Figure 3B).
Discussion
A piecewise U-shaped relationship between age and LN
involvement has been recently reported for two European breast
cancer populations [10]. The present study attempted to validate it
in our study subjects of Chinese breast cancer patients. However,
our results displayed a linear rather than U-shaped relationship.
The linear relationship observed in our first dataset was
subsequently replicated in a second independent dataset. Success-
ful validation strengthens the reliability of our results, indicating
an increase in age related to a continuous decrease in LN
involvement.
There could be a number of reasons responsible for the
inconsistence between our study and the Leuven study. First,
selection bias may be a causal factor. Results from the National
Surgical Adjuvant Breast Project-B04 trial had demonstrated that
ALND did not improve survival in patients with clinically negative
axillary nodes [15]. Subsequent clinical trials demonstrated that
there was no significant survival difference between ALND and no
axillary dissection in the selected patients with older age small
tumor, and clinically negative axilla LNs [16–19]. Therefore, in
clinical practice, a certain number of early stage elderly patients
received lumpectomy or simple mastectomy only without ALND.
Table 2. Univariante and multivariate logistic regression for lymph node involvement in the first and the second dataset.
Independent variable Univariate analysis Multivariate analysis
OR 95% CI P-value HR 95% CI P-value
The first study (n=3,715)
Age (continuous) 0.985 0.979–0.990 ,0.001 0.985 0.979–0.991 ,0.001
Size (continuous) 1.244 1.182–1.310 ,0.001 1.262 1.197–1.331 ,0.001
Pathology (Ductal vs. Lobular vs. Other) 0.625 0.551–0.709 ,0.001 0.614 0.540–0.699 ,0.001
Subtypes (Luminal-like vs. ERBB+ vs. Basal-like) 1.773 1.543–2.037 ,0.001 1.303 1.203–1.411 ,0.001
The second study (n=1,832)
Age (continuous) 0.986 0.978–0.994 0.001 0.989 0.980–0.997 0.009
Size (continuous) 1.409 1.302–1.524 ,0.001 1.416 1.309–1.533 ,0.001
Pathology (Ductal vs. Lobular vs. Other 0.565 0.449–0.711 ,0.001 0.558 0.439–0.710 ,0.001
doi:10.1371/journal.pone.0011035.t002
Table 3. Subgroup analysis of the relationship between age and lymph node involvement by tumor size.
Size (cm) Age (year) First dataset Combining two datasets
LN-negative LN-positive LN-negative LN-positive P-value
n% n% n % n %
#2.0 ,40 98 60.9 63 39.1 174 60.6 113 39.4 0.020
40–49 317 58.5 225 41.5 501 59.8 337 40.2
50–59 294 58.3 210 41.7 490 59.6 332 40.4
60–69 153 65.1 82 34.9 249 66.2 127 33.8
$70 87 70.2 37 29.8 133 70.0 57 30.0
2.1–3.5 ,40 56 41.2 80 58.8 94 43.1 124 56.9 0.002
40–49 235 52.9 209 47.1 315 51.6 295 48.4
50–59 219 53.9 187 46.1 351 54.3 296 45.7
60–69 141 60.8 91 39.2 209 58.2 150 41.8
$70 74 64.3 41 35.7 99 60.0 66 40.0
$3.6 ,40 27 28.4 68 71.6 32 24.8 97 75.2 ,0.0001
40–49 115 43.6 149 56.4 133 39.6 203 60.4
50–59 81 36.3 142 63.7 108 35.9 193 64.1
60–69 65 51.6 61 48.4 74 48.4 79 51.6
$70 56 51.9 52 48.1 63 54.3 53 45.7
doi:10.1371/journal.pone.0011035.t003
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node status available. As a result, a higher percentage of LN
involvement was observed in the older population. This conser-
vative therapeutic strategy seems to be more prevalent in Europe
[16–19]. In China, however, only a slight proportion of elderly
patients were subjected to simple mastectomy or lumpectomy
without ALND [3]. The dataset which we used included all the
consecutive patients who underwent surgery during the studied
period. Every operable elderly patient was included despite her
disease stage. In the Leuven study, however, whether all elderly
patients during the studied period were recruited is unknown.
Second, the epidemiologic difference of breast cancer between the
east and the west could influence the outcomes as well. In most
European and American countries, the peak of breast cancer
incidence was observed in patients .70–75 years old. In contrast,
the incidence peak emerged in the middle-age group (45–60 years)
in Chinese population [2]. Distinct age distribution of breast
cancer patients between the two populations, as well as ethnic
heterogeneity between Europeans and Asians, might make the
nonrepeatability of the piecewise effect of age on LN involvement.
Our results were in line with the results in other studies. Previous
studies suggested that age was negatively associated with node
involvement, and tumor of older patients frequently had ER+
phenotype [9,20–23]. Regarding intrinsic subtypes, we found
decreasing proportions of basal-like subtype (an aggressive pheno-
type) and ERBB2+ subtype (another aggressive phenotype) with
increasing age. Basal-like breast cancer is associated with higher
grade, younger age, higher probability of node involvement and
poor prognosis [11,24,25]. Luminal-like tumors, however, have a
good biologic behavior and are more frequently observed in older
patients [20,23,26]. Additionally, a special type, mucinous breast
carcinoma, is more likely to occur in elderly patients. Mucinous
carcinomas have substantially less nodal involvement, have higher
expression rates of ER and/or PR, and have a lower S-phase
fraction, compared with infiltrating ductal carcinoma [27]. The
features mentioned above may determine the indolent nature of
breast cancers in elderly women, implying that advancing age is
associated with more favorable tumor biology and less involved
LNs. Nowadays, sentinel lymph node biopsy (SLNB)has become an
alternative procedure of ALND. SLNB presents a lower risk of
significant operative morbidity but similar benefit, and has emerged
as the milestone advance in the surgical management of early-stage
primary breast cancer [28,29]. In our hospital, the proportion of
SLNB in the early breast cancer is relatively low (approximately
10%). Considering the low number of SLNB performed in our
hospital and the low false-negative rate (,5%), we did not think
SLNB would cause obvious bias of this study.
Some limitations of our study should be acknowledged. First,
the first dataset had missing values of tumor grade, and the second
dataset included no information on ER/PR/HER2 status. High
percentage of missing values could result in increased likelihood of
biased results. We predicted the probability of LN involvement
using partial independent variables; a stable, robust linear
relationship was repeatedly observed in different models. Second,
the studied period of the first dataset was fairly long. There should
be unavoidable biases in surgical procedure, histopathology
evaluation, and ER/PR/HER2 detection. Third, the second
dataset for validation, although independent, was also derived
from the entire database, which could have increased the
probability of successful validation. Fourth, in our Chinese
database, the proportion of $80 years-old patients was low, and
there were only 79 women with age $80 years, even after
combining these two datasets. The small proportion of elderly and
the under-representation of the $80 years-old group might
explain the lack of reproducibility.
So far, most studies showed a linear rather than piecewise
relationship between age and LN involvement. Some observations
in the Leuven study are not straightforward to explain. Typically,
although the authors offered the possible biologic reasons for their
findings, such as the possibility that suppressed cellular immunity
in the elderly might offset the favorable tumor biology, this
explanation was not consistent with the observation that the
increased rate of axillary node involvement in older patients versus
younger patients was only limited to patients with smaller tumors
[30]. We stress that the novel piecewise relationship should be
further verified in other populations.
In conclusion, we confirmed a straightforward but not piecewise
relationship between age and LN status in Chinese breast cancer
patients. The U-shaped relationship observed in European breast
cancer patients does not appear to be applicable to breast cancer
patients in China. The ethnic differences in LN involvement in
elderly patients should be considered when making clinical
decisions, as well as when establishing global clinical practice
guidelines.
Author Contributions
Conceived and designed the experiments: KDY GHD ZZS ZMS.
Performed the experiments: KDY. Analyzed the data: KDY JJL GHD
JW. Contributed reagents/materials/analysis tools: JW ZZS ZMS. Wrote
the paper: KDY JJL.
References
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2006) Cancer statistics, 2006.
CA Cancer J Clin 56: 106–130.
2. Fan L, Zheng Y, Yu KD, Liu GY, Wu J, et al. (2009) Breast cancer in a
transitional society over 18 years: trends and present status in Shanghai, China.
Breast Cancer Res Treat in press.
3. Yu KD, Di GH, Wu J, Lu JS, Shen KW, et al. (2007) Development and trends of
surgical modalities for breast cancer in China: a review of 16-year data. Ann
Surg Oncol 14: 2502–2509.
4. de Boer M, van Dijck JA, Bult P, Borm GF, Tjan-Heijnen VC (2010) Breast
cancer prognosis and occult lymph node metastases, isolated tumor cells, and
micrometastases. J Natl Cancer Inst 102: 410–425.
5. Hogan BV, Peter MB, Shenoy H, Horgan K, Shaaban A (2010) Intramammary
lymph node metastasis predicts poorer survival in breast cancer patients. Surg
Oncol 19: 11–16.
6. Rutgers EJ (2008) Sentinel node biopsy: interpretation and management of
patients with immunohistochemistry-positive sentinel nodes and those with
micrometastases. J Clin Oncol 26: 698–702.
7. Molino A, Giovannini M, Auriemma A, Fiorio E, Mercanti A, et al. (2006)
Pathological, biological and clinical characteristics, and surgical management, of
elderly women with breast cancer. Crit Rev Oncol Hematol 59: 226–233.
8. Diab SG, Elledge RM, Clark GM (2000) Tumor characteristics and clinical
outcome of elderly women with breast cancer. J Natl Cancer Inst 92: 550–
556.
9. Singh R, Hellman S, Heimann R (2004) The natural history of breast carcinoma
in the elderly: implications for screening and treatment. Cancer 100: 1807–1813.
10. Wildiers H, Van Calster B, van de Poll-Franse LV, Hendrickx W, Roislien J,
et al. (2009) Relationship between age and axillary lymph node involvement in
women with breast cancer. J Clin Oncol 27: 2931–2937.
Figure 3. Scatterplots of age and the model’s predicted probability of lymph node involvement. These patients have complete data on
age at diagnosis, tumor size, axillary lymph node status, and IHC-based subtypes. Separate plots are shown for (A) the first dataset (n=3,715) and (B)
the second dataset (n=1,832), and for women with tumor size up to 2.0 cm (top plots), tumor size between 2.1 and 3.5 cm (middle plots), and tumor
size greater than 3.5 cm (bottom plots).
doi:10.1371/journal.pone.0011035.g003
Age and Node in Breast Cancer
PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e1103511. Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, et al. (2009) Clinicopathological
features of the triple-negative tumors in Chinese breast cancer patients. Breast
Cancer Res Treat 115: 325–333.
12. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000)
Molecular portraits of human breast tumours. Nature 406: 747–752.
13. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene
expression patterns of breast carcinomas distinguish tumor subclasses with
clinical implications. Proc Natl Acad Sci U S A 98: 10869–10874.
14. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race,
breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama
295: 2492–2502.
15. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, et al. (2002) Twenty-five-
year follow-up of a randomized trial comparing radical mastectomy, total
mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347:
567–575.
16. Veronesi U, Orecchia R, Zurrida S, Galimberti V, Luini A, et al. (2005)
Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess
the role of axillary radiotherapy. Ann Oncol 16: 383–388.
17. Martelli G, Boracchi P, De Palo M, Pilotti S, Oriana S, et al. (2005) A
randomized trial comparing axillary dissection to no axillary dissection in older
patients with T1N0 breast cancer: results after 5 years of follow-up. Ann Surg
242: 1–6. discussion 7–9.
18. Louis-Sylvestre C, Clough K, Asselain B, Vilcoq JR, Salmon RJ, et al. (2004)
Axillary treatment in conservative management of operable breast cancer:
dissection or radiotherapy? Results of a randomized study with 15 years of
follow-up. J Clin Oncol 22: 97–101.
19. Martelli G, Miceli R, De Palo G, Coradini D, Salvadori B, et al. (2003) Is
axillary lymph node dissection necessary in elderly patients with breast
carcinoma who have a clinically uninvolved axilla? Cancer 97: 1156–1163.
20. Ma CD, Zhou Q, Nie XQ, Liu GY, Di GH, et al. (2009) Breast cancer in
Chinese elderly women: pathological and clinical characteristics and factors
influencing treatment patterns. Crit Rev Oncol Hematol 71: 258–265.
21. Yu KD, Di GH, Wu J, Lu JS, Shen KW, et al. (2008) Breast cancer patients with
estrogen receptor-negative/progesterone receptor-positive tumors: being youn-
ger and getting less benefit from adjuvant tamoxifen treatment. J Cancer Res
Clin Oncol 134: 1347–1354.
22. Yu KD, Liu GY, Di GH, Wu J, Lu JS, et al. (2007) Progesterone receptor status
provides predictive value for adjuvant endocrine therapy in older estrogen
receptor-positive breast cancer patients. Breast 16: 307–315.
23. Crivellari D, Aapro M, Leonard R, von Minckwitz G, Brain E, et al. (2007)
Breast cancer in the elderly. J Clin Oncol 25: 1882–1890.
24. Rakha EA, El-Sayed ME, Reis-Filho J, Ellis IO (2009) Patho-biological aspects
of basal-like breast cancer. Breast Cancer Res Treat 113: 411–422.
25. Lee JH, Kim SH, Suh YJ, Shim BY, Kim HK (2010) Predictors of Axillary
Lymph Node Metastases (ALNM) in a Korean Population with T1-2 Breast
Carcinoma: Triple Negative Breast Cancer has a High Incidence of ALNM
Irrespective of the Tumor Size. Cancer Res Treat 42: 30–36.
26. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Buttarelli M, et al. (2009)
How different are luminal A and basal breast cancers? Int J Cancer 124:
1338–1348.
27. Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, et al. (1999) Tumor
characteristics and clinical outcome of tubular and mucinous breast carcinomas.
J Clin Oncol 17: 1442–1448.
28. Takei H, Kurosumi M, Yoshida T, Ishikawa Y, Hayashi Y, et al. (2010) Axillary
lymph node dissection can be avoided in women with breast cancer with
intraoperative, false-negative sentinel lymph node biopsies. Breast Cancer 17:
9–16.
29. Giuliano AE, Chung AP (2010) Long-term follow-up confirms the oncologic
safety of sentinel node biopsy without axillary dissection in node-negative breast
cancer patients. Ann Surg 251: 601–603.
30. Mamounas EP (2009) Age and lymph node status in breast cancer: not a
straightforward relationship. J Clin Oncol 27: 2900–2901.
Age and Node in Breast Cancer
PLoS ONE | www.plosone.org 8 June 2010 | Volume 5 | Issue 6 | e11035